Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial
- PMID: 20122373
- DOI: 10.4088/JCP.09m05482yel
Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial
Abstract
Objective: To evaluate the efficacy and safety of ziprasidone adjunctive to a mood stabilizer for the maintenance treatment of bipolar mania.
Method: Subjects with DSM-IV bipolar I disorder with a Mania Rating Scale score > or = 14 were enrolled. Subjects achieving > or = 8 consecutive weeks of stability with open-label ziprasidone (80-160 mg/d) and lithium or valproate (period 1) were randomly assigned in the 6-month, double-blind maintenance period (period 2) to ziprasidone plus mood stabilizer or placebo plus mood stabilizer. The primary and key secondary end points were the time to intervention for a mood episode and time to discontinuation for any reason, respectively. Inferential analysis was performed using a Kaplan-Meier product-limit estimator (log-rank test). The study was conducted from December 2005 to May 2008.
Results: A total of 127 and 113 subjects were randomly assigned to ziprasidone and placebo, respectively. Intervention for a mood episode was required in 19.7% and 32.4% of ziprasidone and placebo subjects, respectively. The time to intervention for a mood episode was significantly longer for ziprasidone than placebo (P = .0104). The median time to intervention for a mood episode among those requiring such an intervention (n = 61) was 43.0 days for ziprasidone versus 26.5 days for placebo. The time to discontinuation for any reason was significantly longer for ziprasidone (P = .0047). Adjunctive ziprasidone treatment was well tolerated. Among treatment-emergent adverse events occurring in > or = 5% of subjects in either treatment group during period 2, only tremor occurred more frequently in the ziprasidone versus placebo group (6.3% vs 3.6%).
Conclusions: Ziprasidone is an effective, safe, and well-tolerated adjunctive treatment with a mood stabilizer for long-term maintenance treatment of bipolar mania.
Trial registration: clinicaltrials.gov Identifier: NCT00280566.
Copyright 2010 Physicians Postgraduate Press, Inc.
Similar articles
-
Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.J Clin Psychiatry. 2012 Nov;73(11):1412-9. doi: 10.4088/JCP.11m07388. J Clin Psychiatry. 2012. PMID: 23218157 Clinical Trial.
-
Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults.Expert Rev Neurother. 2010 Jul;10(7):1031-7. doi: 10.1586/ern.10.66. Expert Rev Neurother. 2010. PMID: 20586686 Review.
-
Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.J Clin Psychiatry. 2011 Oct;72(10):1413-22. doi: 10.4088/JCP.09m05934. J Clin Psychiatry. 2011. PMID: 21672493 Clinical Trial.
-
Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.Curr Med Res Opin. 2010 Jun;26(6):1485-96. doi: 10.1185/03007991003779380. Curr Med Res Opin. 2010. PMID: 20429835 Clinical Trial.
-
Adjunctive treatment of acute mania: a clinical overview.Acta Psychiatr Scand Suppl. 2007;(434):27-34. doi: 10.1111/j.1600-0447.2007.01056.x. Acta Psychiatr Scand Suppl. 2007. PMID: 17688460 Review.
Cited by
-
Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis.CNS Drugs. 2013 Jul;27(7):515-29. doi: 10.1007/s40263-013-0073-y. CNS Drugs. 2013. PMID: 23749421 Review.
-
A critical appraisal of treatments for bipolar disorder.Prim Care Companion J Clin Psychiatry. 2010;12(Suppl 1):23-9. doi: 10.4088/PCC.9064su1c.04. Prim Care Companion J Clin Psychiatry. 2010. PMID: 20628503 Free PMC article.
-
The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder.Neuropsychiatr Dis Treat. 2011;7:87-92. doi: 10.2147/NDT.S9932. Epub 2011 Mar 7. Neuropsychiatr Dis Treat. 2011. PMID: 21552310 Free PMC article.
-
Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?Ann Gen Psychiatry. 2011 Mar 24;10(1):8. doi: 10.1186/1744-859X-10-8. Ann Gen Psychiatry. 2011. PMID: 21435226 Free PMC article.
-
Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.J Psychopharmacol. 2016 Jun;30(6):495-553. doi: 10.1177/0269881116636545. Epub 2016 Mar 15. J Psychopharmacol. 2016. PMID: 26979387 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical